Clinical Trial

A Study of ERAS-601 in People With Chordoma

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-04-03
notable Enrollment reduced: 46 -> 12 participants 2026-04-03
Trial Details
NCT Number NCT06957327
Lead Sponsor Memorial Sloan Kettering Cancer Center
Conditions Chordoma
Enrollment 12 participants
Start Date 2025-04-25
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-28